Savara (NASDAQ:SVRA) Price Target & New Coverage by Ladenburg Thalmann
Analysts at Ladenburg Thalmann initiated coverage on Savara (NASDAQ:SVRA) with Buy rating. The target for SVRA is set to $35.0. It indicates a potential upside of 275.94 % from firm’s previous stock close.
The initiation is well received by equity trades, as NASDAQ:SVRA is right now trading 0.64% higher at $9.38 as of 12:04 PM New York time. Savara’s stock is 0% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has added 6.00% over the same time period.
Savara (NASDAQ:SVRA) Profile
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001.
Savara (NASDAQ:SVRA) traded up 0.64% on 3 January, hitting $9.38. A total of 84,855 shares of the company’s stock traded hands. This is down from average of 151,783 shares. Savara has a 52 week low of $4.60 and a 52 week high of $16.23. The company has a market cap of $227.03M and a P/E ratio of 0.
Get the latest Savara (NASDAQ:SVRA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Savara (NASDAQ:SVRA) Stock: Ladenburg Thalmann Has Initiated Coverage with Buy Rating Outlook appeared first on Octafinance.